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Abstract
Myoglobin (MB) is not only strongly expressed in myocytes, but also at much lower levels in
different cancer entities. 40% of breast tumors are MB-positive, with the globin being co-
expressed with markers of tumor hypoxia in a proportion of cases. In breast cancer, MB
expression is associated with a positive hormone receptor status and patient prognosis. In
prostate cancer, another hormone-dependent cancer type, 53% of tumors were recently
shown to express MB. Especially in more aggressive prostate cancer specimen MB expres-
sion also correlates with increased patient survival rates. Both findings might be due to
tumor-suppressing properties of MB in cancer cells. In contrast to muscle,MB transcription
in breast and prostate cancer mainly depends on a novel, alternative promoter site. We
show here that its associated transcripts can be upregulated by hypoxia and downregulated
by estrogens and androgens in MCF7 breast and LNCaP prostate cancer cells, respec-
tively. Bioinformatic data mining of epigenetic histone marks and experimental verification
reveal a hitherto uncharacterized transcriptional network that drives the regulation of the
MB gene in cancer cells. We identified candidate hormone-receptor binding elements that
may interact with the cancer-associatedMB promoter to decrease its activity in breast and
prostate cancer cells. Additionally, a regulatory element, 250 kb downstream of the pro-
moter, acts as a hypoxia-inducible site within the transcriptional machinery. Understanding
the distinct regulation ofMB in tumors will improve unraveling the respiratory protein’s func-
tion in the cancer context and may provide new starting points for developing therapeutic
strategies.
Introduction
The respiratory protein myoglobin (MB) is expressed at high concentrations (~200–300 μM)
in human skeletal and cardiac myocytes and, at much lower levels, in smooth muscle cells [1–
3]. At its prosthetic heme group, the protein is able to bind gaseous ligands, with its main task
being the transport and storage of O2 in myocytes [2,4]. Analyzing diving capacities of deep-
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diving mammals even revealed a direct correlation between myocytic Mb levels and O2 supply
[5]. Although Mb -/- knockout mice are viable, they adapt to the loss of this heme protein by
compensatory mechanisms, such as an increased capillary density and reduced cardiomyocyte
width, to overcome the shortage of O2 supply [6,7]. In addition to its O2 storage/transport
function in the cytoplasm, MB plays a crucial role in the detoxification of reactive oxygen and
nitrogen species, i.e. by converting harmful excess NO to nitrate through the NO-dioxygenase
activity of oxy-MB [8–10]. Under hypoxic conditions, deoxy-MB is instead able to produce
NO, which in turn can inhibit mitochondrial O2 consumption and facilitate vasodilation in
smooth muscle cells [11].
Besides its appearance in myocytes and few other somatic cell types, endogenous expression
of MB has been reported for several tumor entities in humans at comparatively low micromo-
lar levels, e.g. in breast cancer, non-small lung cancer, colon cancer, renal cell carcinoma, pros-
tate cancer, osteosarcoma and leukemic bone marrow [12–18]. To investigate the biomedical
relevance of MB expression in tumors, the survival rate of 917 primary breast cancer cases was
monitored and correlated to their MB expression status. In a Kaplan-Meier analysis, patients
with MB-positive breast tumors faced a beneficial prognostic outcome [15]. Kaplan-Meier
plots of poorly differentiated prostate cancer entities (ranked Gleason 8–10) also showed a
trend towards longer recurrence-free patient survival for MB-positive cases [18]. In contrast,
high MB levels in lung adenocarcinoma correlated with a poor patient prognosis, although the
study only compared the prognostic outcome of patients with high versus low MB-expressing
tumors, but lacked the comparison to MB-negative tumor entities [16].
Up to now, little is known about the distinct function of MB in cancer cells. Signs of
improved oxygenation were found in mice tumors generated by xenotransplantation of A549
lung cancer cells which ectopically expressed lentiviral-induced MB in the quantity range of
skeletal muscle MB levels [19]. Similar to comparing the hearts of Mb -/- knockout versus wild-
type mice, the MB-overexpressing xenotransplant tumors versus MB-negative controls showed
altered vessel densities and reduced levels of the master transcription factor HIF1α, which
accumulates in hypoxic/deoxygenated cells and tissues and triggers transcription activation of
hypoxia-responsive downstream genes [19]. In addition, the MB-overexpressing tumors of
xenotransplanted mice were more differentiated and had reduced local and distal metastatic
spread [19]. In normal epithelial cancer cells, however, the overall MB level was roughly 300
fold lower than in the engineered xenografts [20]. Respirometry measurements in endoge-
nously MB-expressing MDA-MB468 breast cancer cells even displayed lower cellular O2
uptake compared toMB-knockdown cells. Therefore the globin probably does not substantially
contribute to O2 transport or storage in cancer cells [20]. MTT assays on MB-positive breast
cancer cells indicated a decreased mitochondrial dehydrogenase activity compared to knock-
downs under harsh hypoxia, suggesting that the antitumor effect of MB seen in cancer patients
is exerted through mitochondria-impairing activities of the protein [20].
To pave the way for biomedical approaches exploiting such a tumor-suppressing property,
recent studies addressed the mechanisms ofMB gene regulation in cancer cells. Differing from
the transcription machinery primarily active in myocytes,MB is mainly transcribed from a
novel upstream promoter region in both, cancer cell lines and tumor biopsies [18,21]. A multi-
tude of differentially spliced mRNAs possessing different 5’UTR exons but encoding the same
protein sequence was recorded in tumor cells [21]. Amongst them, the mRNA variants 9, 10
and 11, all transcribed from the novel promoter upstream of exon 5u, were shown to be most
prominently expressed [21]. Breast and prostate cancer biopsies revealed a significant correla-
tion between increased levels of the alternativeMBmRNA starting from exon 5u and the
expression of hypoxia-responsive genes [18,21]. Accordingly, a hypoxic induction ofMB
mRNA was observed in breast and colon cancer cell lines cultivated under 1% O2 [21]. In part,
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this effect could be attributed to the transcriptional stimulation ofMB expression by HIF1α
and HIF2α transcription factors [20]. A hypoxia-responsive element (HRE) containing HIF1α
binding sites was identified in an intronic region of theMB gene, which increased reporter
gene expression by 43% in MDA-MB468 cancer cells upon experimental hypoxia [20]. Since
total hypoxic induction ofMB in the same cell line amounted to 3.5 fold, additional enhancer
sites should be involved inMBmRNA upregulation in cancer cells. While investigating MB
protein expression in prostate cancer, a significant positive correlation to androgen-receptor
(AR) staining was observed and the analysis of publicly available transcriptome data suggested
a dihydrotestosterone (DHT)-mediated suppression of theMB gene [18]. Among invasive
breast cancer tumors, MB showed predominant expression in estrogen hormone receptor-pos-
itive, luminal-type breast tumor entities [15]. Estrogen treatment of MCF7 breast cancer cells
resulted in a downregulation ofMBmRNA expression, although the studies did not specify
whichMB variants were affected [14,15].
Thus, gene regulation ofMB in the tumor context is complex and far from being understood
in detail. To decipherMB’s regulatory components, we applied bioinformatic analyses of high-
throughput sequencing data and identified novel potential enhancer regions that may interact
with theMB promoter and participate in the regulatory network that triggersMB expression in
tumors. Moreover, we investigated the influence of hypoxia and hormones onMB transcrip-
tion, linking these stimuli to MB-associated patient prognoses.
Materials and Methods
Bioinformatic analyses ofMB expression in differently treated cancer
cells
To investigate the influence of estrogens, androgens and hypoxia on the splice variant-specific
MB expression in MCF7 and LNCaP cells, RNA-Seq transcriptome datasets (see S1 Table for
accession numbers) were downloaded from the NCBI sequence read archive (SRA) and pro-
cessed with the CLC Genomics Workbench 6.5.1. (CLC Bio, Qiagen). Illumina adapters and
low quality sequences (below 0.05) were filtered and 12 bp were trimmed from the 5’end and 5
bp at the 3’end. The minimum sequence length was set to 15 bp, allowing up to two ambiguous
nucleotides. Processed reads were then mapped against the annotated Homo sapiens genome
(hg19, GRCh37), using the CLC Genomics Workbench 5.6.1 RNA-Seq tool at default settings
with a maximum of 2 mismatches. Reads that mapped to the coordinates of either one of the
MB gene’s (NG_007075.1) alternative start exons (1u, 2u, 4u, 5u, 8u, 9u, 10u) were counted
and normalized on the according exon length and dataset size, generating RPKM values (here:
reads per exon size in kb per 1 mio. mapped reads).
GRO-Seq datasets downloaded from the NCBI-SRA (accession numbers in S1 Table) were
processed with the CLC Genomics Workbench 6.0.4. (CLC Bio, Qiagen) Illumina adapters and
12 bp at each read’s 5’end were trimmed with a minimum remaining sequence length of 10 bp.
The quality limit filter was set to 0.01 and up to two ambiguous nucleotides were allowed. Map-
ping (CLC Genomics Workbench 6.0.4 tool RNA-Seq) was performed at default parameters
with 3 mismatches at maximum. Reads mapping within the region 100 bp upstream to 500 bp
downstream of each transcript’s start site were counted and normalized relative to the fragment
size (0.6 kb) and the size of the dataset to generate RPKMs.
For RNA-Seq and GRO-Seq data, boxplots and One Way ANOVA statistics (p<0.05) fol-
lowed by Tukey-Kramer post hoc tests when appropriate were conducted with Excel 2010
(Microsoft). Asterisks indicate statistically significant differences comparing (i) differences
between RPKMs of control cell batches and treatment batches for each start site and (ii) differ-
ences between RPKMs of the standard MB start site 9u to all other start sites.
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Genomic datasets of epigenetic DNA marks including ChIP-Seq, FAIRE-Seq and Bisulfite-
Seq (see S2 Table for accession numbers) were downloaded from the NCBI-SRA, the NCBI--
GEO, and the EMBL-EBIArrayExpress databases (http://www.ebi.ac.uk/arrayexpress). All
datasets were processed with the Genomatix Mining Station (Genomatix Software). Prior to
mapping, reads of a Phred score lower than 30 were rejected and 15 bp at the 5’end and 5 bp at
the 3’end of each read were masked. Reads were then mapped to the Homo sapiens Genome
(NCBI built 37) using the ElDorado tool version 08–2011 at a minimummatch accuracy of
92%. For all datasets, the options deep mapping andmap with insertions/deletions were chosen.
Bisulfite-treated datasets were additionally mapped against accordingly modified genome
versions.
For better dataset handling, only bisulfite mapping results on chromosome 22 were
inspected and thus reduced unique mapping reads to those, which align to chromosome 22 by
applying the Galaxy platform Filter tool 1.1.0 (http://galaxyproject.org). For visualization of
methylated and unmethylated sites all datasets were converted into UCSC custom tracks by the
Genomatix Genome Analyzer (GGA; Genomatix Software) Bed File Toolbox.
Mappings of ChIP-Seq datasets and according input-files were processed with the GGA
ChIP-Seq workflow tool. Peak calling was done with the Genomatix NGS Analyzer tool at a
window size of 50 bp and with the minimum number of reads per peak being automatically cal-
culated by applying a Poisson distribution. For evaluation of clusters, EdgeR statistics were
applied at (p<0.05); Threshold: log2(fold change) 1 for enrichment and log2(fold change)
-1 for depletion. The generated ChIP-peak coordinates and the FAIRE-Seq mappings were
again reformatted to UCSC custom tracks by the GGA Bed File Toolbox.
To gain more comprehensive information about the epigenetic profile ofMB expressing
cancer cell lines, additional mapping files were downloaded (S2 Table), including those gener-
ated by DNAse I HS-Seq and ChIA-PET and additional FAIRE-Seq and ChIP-Seq files
[sources: The ChIA-PET Browser (http://chiapet.gis.a-star.edu.sg/); NCBI-GEO; EMBL-E-
BIArrayExpress database and the Database of Transcriptional Start Sites (http://dbtss.hgc.jp)].
Peak calling of DNAse I HS-Seq mappings was accomplished as described above for ChIP-Seq
outputs. All datasets were transformed into UCSC custom tracks. Site-specific comparison and
interpretation of generated custom tracks was performed in the UCSC genome browser
(https://genome.ucsc.edu).
Cell culture conditions
The breast cancer cell line MCF7 (gift by Prof. Dr. Pflugfelder, originally from ATCC;
ATCC-HTB22) and the prostate cancer cell line LNCaP (gift by Dr. Szafranski, originally from
DSMZ; ACC256) were cultured with phenol red-free DMEM (PAN P04-01158) and phenol
red-free RPMI1640 (PAN P04-16516), respectively, both supplemented with stable glutamine
(PAN), 10% FBS Gold (PAA) and 1% Pen/Strep (PAA). Incubation took place in an IG150
incubator (Jouan) at 37°C and 5% CO2 in a H2O-saturated atmosphere for normoxic culture
conditions, while experimental hypoxia was provided in a CB 53 incubator (Binder) at 37°C,
1% O2 and 5% CO2 in a H2O-saturated atmosphere. Approval of Mycoplasm negativity was
conducted with the VenorGeMMycoplasma PCR detection kit (Minerva Biolabs). Both cell
lines were authenticated by their SNP profiles (Multiplexion).
RNA preparation and quantitative real-time reverse-transcriptase PCR
(qRT-PCR)
RNA from LNCaP cells raised under normoxia or at 1% O2 for 24 h was extracted with the
RNeasy Mini Kit (Qiagen), including an on-column DNAse I digestion. RNA integrity was
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approved to be>9.2 by running on an Agilent 2100 Bioanalyzer. The superscript III RT kit
(Life technologies) was used for cDNA synthesis from 900 ng of LNCaP RNA.MB variants
were quantified by qRT-PCR with a standard curve approach as described in [21]. A primer
list can be found in (S3 Table). For amplification, GoTaq qPCRMaster Mix (Promega) was
used in a total volume of 10 μl. Reactions were carried out in an ABI 7500 Fast Real Time PCR
system (Applied Biosystems) at an annealing temperature of 57°C. Triplicate assays were mea-
sured in each run with a total of n = 3 biological replicates. For calibration, we quantified
LMNB1 mRNA in each sample (primers enlisted in S3 Table) and thus normalized the quan-
tity of eachMB variant to the housekeeping gene. Boxplots were generated and One Way
ANOVA statistics (p<0.05) with post hoc Tukey-Kramer tests were conducted with Excel 2010
(Microsoft). Asterisks show statistically significant differences (i) between normoxia cells and
1% O2 cells for each mRNA variant and (ii) between the standardMB transcript variant 2 and
all other transcript variants in normoxic cells.
Functional analysis of potentialMB enhancers by dual luciferase
reportergene assays (DLRA)
In silico investigations of epigenetic histone marks revealed nine DNA regions, which poten-
tially trigger the transcriptional activity of the cancer activeMB exon 5u promoter. These
regions were amplified with the KAPAHiFi PCR Kit (Peqlab) on genomic DNA of MCF7 cells.
At their 5’ends, forward and reverse PCR-primers were equipped with MluI and XhoI restric-
tion enzyme recognition sites, respectively (S3 Table). For cloning purposes, PCR amplicons
and luciferase reporter gene vectors (pGL3-promoter vectors, Promega) were digested with
FastDigest MluI and FastDigest XhoI enzymes (Thermo Scientific). After dephosphorylation
of the 5’ends of the vector by the FastAP Thermosensitive Alkaline Phosphatase (Thermo Sci-
entific), T4 ligase (Thermo Scientific) was used to ligate the PCR products into pGL3 vectors.
The samples were transformed into DH10B bacteria host cells, selected and raised for plasmid
preparations with the PureYield Plasmid Miniprep System (Promega). Sanger-based sequenc-
ing (StarSEQ) approved the accuracy of the cloned inserts. Alongsite with the reportergene
constructs of potential enhancers, a 2072 bp spanning PCR amplicon of theMB exon 5u pro-
moter region (S3 Table) was cloned into the pGL3 control vector (Promega) as described in
[21].
To investigate the impact of the cloned promoter and enhancer sites on the target genes’
transcriptional efficiencies, reporter gene assays were conducted. To this end, ~104 LNCaP or
MCF7 cells were seeded in white Polystyrene 96 well plates (Thermoscientific, 136101) and
transfected with a mixture of 91 μg pGL3 firefly luciferase plasmid, 9 μg pGL4.74 renilla lucifer-
ase vector (Promega) as an internal control and 0.2 μl FuGeneHD transfection reagent (Pro-
mega). 44 h post transfection, DLRA measurements were carried out in triplicates in a Glomax
96 well luminometer (Promega). For each well, 40 μl of both DLRA-system reagents (Promega)
were used. Firefly light units originating from pGL3 plasmids were normalized on renilla sig-
nals to calculate the relative light units (RLU) for each well. For each plate, samples were fur-
ther normalized on their cloned insert size and the RLUs measured for the empty vector. RLUs
of cells treated with 100 nM estrogen (E2) for 1 h or 100 nM androgen (DHT) for 3 h prior to
luciferase assays were divided by the RLUs measured of control cells transfected with the equiv-
alent plasmid but mock-treated with ethanol. Boxplots and two-sided Student’s T-tests to test
for significance were calculated with Excel 2010 (Microsoft).
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Results
Hypoxia increasesMB expression in prostate and breast cancer cells
In prostate cancer biopsies, mainly the alternativeMB variants starting at upstream exon 5u
were transcribed, while theMB transcript mainly expressed in myocytes (starting with exon
9u; Fig 1a) was hardly detectable [18]. To investigate if this regulatory pattern also applies to
the prostate cancer cell line LNCaP, we performed splice variant-specific quantification ofMB
mRNAs by quantitative real-time reverse-transcriptase PCR (qRT-PCR). As in biopsies,
LNCaP cells predominantly expressed transcripts starting with exon 5u. For comparison,MB
mRNAs starting at exon 9u were expressed almost 2000 fold less than the variants starting at
exon 5u (Fig 1b).
Previously, a 1.5 to 3.5 fold hypoxia-driven upregulation of theMB exon 5u mRNAs has
been reported in two epithelial cancer cell lines of breast (MDA-MB468) and colon (DLD-1)
origin [21]. In line with this, qRT-PCRs revealed on average a moderate 2.8 fold hypoxic induc-
tion ofMB exon 5u transcripts in LNCaP cells (Fig 1b). To further monitor the effect of hyp-
oxia onMB regulation in a second breast cancer cell line, MCF7, RNA-Seq data obtained from
cells subjected to 1% O2 and normoxia for 24 h were downloaded (S1 Table) and mapped
against the human reference genome. According to normalized read counts, hypoxic MCF7
cells expressed about 4.3 fold the amount of exon 5uMB transcripts than normoxic cells (Fig
1c). Hypoxia inducibility ofMBmRNAs starting with exon 4u was 1.2 fold, with a relative
exon 4u mRNA abundance of only 26% compared to the exon 5u transcripts under hypoxia.
The exon 9uMB transcripts, most prominently expressed in myocytes, were not detected in
MCF7 (Fig 1c, S1 Table). According tendencies were observed in an additional study (S1a Fig).
Altogether, these expression data justify broad usage of the LNCaP and MCF7 cell models to
study theMB gene regulatory network ofMB primarily active in cancer cells.
Downregulation ofMB in prostate and breast cancer cell lines upon
hormone treatment
To investigate how hormone application affects the expression ofMB in LNCaP prostate can-
cer cells, transcriptome datasets treated with the androgen methyltrienolone (R1881) and sol-
vent-treated control cells were evaluated for transcript-specificMB expression by read
mapping (S1 Table). The vast majority ofMBmRNAs expressed in LNCaP cells started at
exons 5u and 4u. In contrast, theMBmRNA types predominant in myocytes were detected at
much lower levels (e.g. exon 9u transcripts were expressed 214 fold less than exon 5u mRNAs;
Fig 2a, S1 Table). Compared with controls, expression ofMB exon 5u mRNAs in LNCaP cells
incubated with 1 nM R1881 for 12 h was decreased to 64%. Exon 4u mRNA levels also slightly
decreased to 82% after R1881 treatment (Fig 2a). In silico analysis of an independent second
RNA-Seq dataset of R1881-treated LNCaP cells revealed that the androgen-mediated decrease
ofMBmRNAs occurred in a time-dependent manner (S2 Fig). After 24 h and 48 h, exon 5u
mRNA levels decreased to 32% and 16%, respectively, and exon 4u transcripts to 37% and
23%, relative to androgen-free controls (S2 Fig).
Initiated by the finding thatMB transcription decreased in prostate cancer cells upon andro-
gen treatment, we further investigated the potential effect of estrogen application onMB
expression in the breast cancer cell line MCF7. To this end, RNA-Seq and Genomic Run-On
sequencing (GRO-Seq) datasets of MCF7 cells either treated with 17β-estradiol (E2) or ethanol
as control were downloaded and mapped against the human genome. Splice variant-specific
read counting indicated that again the mRNAs starting at exon 5u were most abundantly
expressed in the breast cancer cell line (Fig 2b). Compared to these exon 5u variants, about
The Gene Regulatory Network of Myoglobin in Cancer
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Fig 1. Expression analysis ofMB transcript variants in normoxic and hypoxic (1%O2, 24 h) cancer cells. (a) Architecture of the humanMB gene.
Boxes indicate exons, arrows mark transcription start sites (TSS) with the most active ones being labelled, based on [21]. (b)Quantification of cDNA copy
numbers in LNCaP cells, measured in triplicate assays by transcript-specific qRT-PCR and normalized on LMNB1 controls (n = 3; * p < 0.05). mRNA copy
numbers per 40 ng LNCaP total RNA are shown in box plots. (c) In silico quantification ofMB transcripts by RNA-Seq analysis of MCF7 breast cancer cells
(n = 2). Read counts are shown as RPKM values (* p < 0.05). Expression values are detailed in S1 Table.
doi:10.1371/journal.pone.0142662.g001
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Fig 2. RNA-Seq based quantification ofMB transcript variants in hormone treated cancer cells. (a) Box plots ofMB variant expression in androgen
(R1881) treated LNCaP cells after 12h versus non-treated controls (n = 3; * p < 0.05). Average transcript-specific expression values are listed in S1 Table.
(b)MB variant expression in estrogen (E2) treated MCF7 cells after 24 h versus non-treated controls (n = 7). RPKM values of RNA-Seq read counts are
shown as box plots, representing transcriptional levels of the differentMB start exons (* p < 0.05). Average transcript-specific expression values are given in
S1 Table.
doi:10.1371/journal.pone.0142662.g002
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60% fewer transcripts starting at exon 4u were counted, while the muscle-associatedMB tran-
scripts were hardly detectable in MCF7 (S1 Table). After 24 h of E2 treatment,MB exon 5u
mRNA expression decreased to 40% compared to controls, while exon 4u transcripts were
downregulated to 55% upon hormone administration (Fig 2b). As previously observed in
LNCaP cells, GRO-Seq data showed that the estrogen-driven downregulation of exon 5uMB
transcripts in MCF7 cells also occurred in a time-dependent manner (S1b Fig). Treatment with
100 nM E2 resulted in a decrease of exon 5u mRNAs to 70% after 10 min, to 47% after 25 min
and to 24% after 40 min. For the exon 4u variant, a more moderate downregulation to 85% was
monitored when comparing cells incubated with E2 for 40 min to the control cells (S1b Fig).
Long-range interactions between distal DNA elements and the cancer-
associatedMB promoter
Although the cancer-activeMB promoter region was previously defined to be located in an
interval 179 bp upstream to 25 bp downstream of exon 5u [21], little is yet known about its spe-
cific regulatory network. To this end, we studied publically available ChIA-PET (Chromatin
interaction analysis by paired-end tag sequencing) datasets of MCF7 cells, which endogenously
expressMB. Each ChIA-PET marks two DNA regions that backloop in close proximity to each
other, being specifically bound by proteins, i.e. transcription factors, which interact with each
other [22]. Many of the RNA-Polymerase II-associated ChIA-PETs produced by the ENCODE
consortium originate in theMB exon 5u promoter region and span to either one of five regions
downstream (A-E) or one of two regions upstream (F, G) of theMB gene (Fig 3), encompassing
a genomic region of 280 kb. Promoter interaction of three of these regions (B, C and G) was
confirmed by RNA-PolII ChIA-PET tracks from independent datasets of the Gene Expression
Omnibus (GEO) database (Fig 3). We further detected intrachromosomal inter-ligation
ChIA-PETs, which reflect connections between enhancer regions, thus indicating the forma-
tion of a cloverleaf-like chromatin loop network around theMB exon 5u promoter.
In addition, ENCODE-UCSC tracks from CCCTC-binding factor (CTCF) ChIA-PET
experiments indicated that regions B and D are bound by CTCF transcription factors while
interacting with theMB exon 5u promoter via three-dimensional looping structures. DNA
regions in close proximity to regions A and C are also bound by CTCF, possibly triggering the
formation of a chromatin loop architecture (Fig 3). Region F also matches CTCF peaks, but the
investigated ChIA-PET tracks lack evidence that this site directly interacts with theMB exon
5u promoter when bound to CTCF.
Chromatin modifications at candidateMB enhancer sites
To determine whether DNA regions A to G, which potentially interact with theMB exon 5u
promoter based on ChIA-PET analyses, are indeed transcriptionally active, we investigated
their chromatin status in more detail. Data mining of DNAse I hypersensitive site (DNAse I
HS) peaks revealed that all of the sites hypothetically interacting with the promoter were
indeed accessible for transcription factors in MCF7 cells, including theMB exon 5u promoter
itself (Fig 4a and 4b). Additional DNAse I datasets from LNCaP cells also confirmed the pro-
moter site and showed that all ChIA-PET matching DNA regions (despite G, where evidence
was lacking) had an open chromatin status in prostate cancer cells. Analyzing chromatin
immunoprecipitation sequencing (ChIP-Seq) datasets revealed a subset of histone marks
(H3K4me1, H3K27ac) and basal components of the transcription machinery (e.g. PolII, p300)
in each of the candidate regulatory DNA regions A1 to G, thus adding evidence to their
involvement in transcriptional regulation (Fig 4b).
The Gene Regulatory Network of Myoglobin in Cancer
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Fig 3. UCSC browser overview of ChIA-PET interactions around the 5uMB promoter in MCF7 cells. Top: UCSC annotation ofMB and a custom track
of all humanMB exons, according to [21]. Bottom: UCSC browser and custom tracks with ChIA-PET coordinates. Dataset specifications are listed on the
right. Asterisks indicate DNA regions that directly interact with theMB promoter. The green vertical line indicates the 5uMB promoter region.
doi:10.1371/journal.pone.0142662.g003
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Hypoxia-drivenMB gene regulation by enhancer sites
A possible activation ofMB enhancer regions by hypoxia was investigated on the basis of
DNAse I and ChIP-Seq datasets. No hypoxia-associated datasets of chromatin marks from
LNCaP cells were available in public databases. However, DNAse I HS-Seq datasets of hypoxic
MCF7 breast cancer cells and normoxic controls showed that eight out of nine ChIA-PET
regions (except for E, where peaks were absent) and theMB exon 5u promoter region featured
open chromatin not only under normoxia, but also under hypoxic culture conditions and thus
were accessible for transcription factors. In DLD-1 colon cancer cells, which also endogenously
expressMB [21], RNA-PolII ChIP-Seq peaks confirmed the candidate enhancer regions A1, G
and F to be active under both, hypoxia and normoxia (Fig 5a).
Fig 4. UCSC browser overview of ChIA-PET interactions and chromatin modifications around theMB exon 5u promoter. (a)UCSC annotation ofMB
and a custom track of all humanMB exons, according to [21]. (b) UCSC browser and custom tracks with ChIA-PET coordinates. Chromosome 22
coordinates are written on top. The respective dataset specifications are listed on the right, grouped according to data showing open chromatin, histone
modifications and transcription factor binding. Dark boxes in the upper section connected by thin lines reflect candidate interacting sequence regions
according to ChIA-PET sequencing technique data mining. (c) Blue boxes indicate candidate enhancer regions, including theMB exon 5u promoter and
DNA regions that directly interact with it based on ChIA-PET data and accumulative evidence from epigenetic marks as detailed above. The table further
summarizes Fig 5a, Figures a in S3 and S4 Figs, crossmarking (X) which DNA sites show hypoxia-, androgen- and estrogen-associated chromatin
modifications detected by ChIP-Seq and FAIRE-Seq.
doi:10.1371/journal.pone.0142662.g004
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ChIP-Seq experiments on MCF7 cells using either HIF1α or HIF1β antibodies indicated
possible binding sites of the hypoxia-responsive master transcription factor HIF1 (Fig 5a). Our
analyses revealed a HIF1α peak only for region A1, and this HIF1α peak is in close proximity
to a HIF1β peak, whereby this region is most likely bound by the HIF dimer under hypoxia.
Dual luciferase reportergene assays (DLRA) conducted in MCF7 and LNCaP cells with trans-
fected plasmids containing either one of the potential enhancer regions A to G proved the hyp-
oxia-responsiveness of region A1 in both cancer cell types. Compared to normoxia, relative
light units increased 3.2 fold in MCF7 cells and 1.8 fold in LNCaP cells, when culturing each
cell line transfected with A1 constructs under 1% O2 (Fig 5b and 5c). Noteworthy, this candi-
date enhancer site A1 is located about 250 kb downstream of theMB exon 5u promoter. Bind-
ing of the HIF dimer transcription factor to A1 is likely to occur at an in silico predicted HRE
sequence motif in the A1 DNA region (Fig 6a).
Candidate enhancer region E also increasedMB exon 5u promoter activity in MCF7 cells
(1.9 fold) under hypoxia (Fig 5c). However, this enhancer effect was not detected by DLRAs in
Fig 5. Identification of hypoxia associated regulatory regions of theMB gene. (a)UCSC browser overview of hypoxia associated chromatin
modifications around the 5uMB promoter in MCF7 and DLD-1 cells. Top: UCSC annotation of the humanMB gene and a custom track of all humanMB
exons, according to [21]. Bottom: UCSC browser and custom tracks. Dataset specifications are listed on the right. The green shattered box indicates the 5u
MB promoter region. The red shattered boxes mark the DNA regions that directly interact with the 5uMB promoter site based on ChIA-PET data. The naming
of the regions to match the DLRAmeasured constructs is written in the bottom line. (b) Hypoxia inducibility of theMB 5u promoter and interacting DNA
regions in LNCaP cells. DLRAs were measured on hypoxia (1% O2 for 72 h) and normoxia incubated cells transfected with reportergene plasmids with
different DNA regions. Box plots indicate the average RLU fold change of each construct under hypoxia versus normoxia growth conditions after
normalization on empty vector constructs and renilla control vectors. Standard deviations are indicated by error bars (n = 3; *** p < 0.001). (c) Hypoxia
inducibility of theMB 5u promoter and interacting DNA regions in MCF7 cells. DLRAs were measured on hypoxia (1%O2 for 72 h) and normoxia incubated
cells transfected with reportergene plasmids with different DNA regions. Box plots indicate the average RLU fold change of each construct under hypoxia
versus normoxia growth conditions after normalization on empty vector constructs and renilla control vectors. Standard deviations are indicated by error bars
(n = 3; * p < 0.05; ** p < 0.01).
doi:10.1371/journal.pone.0142662.g005
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LNCaP cells. We also did not find DNAse I HS or formaldehyde assisted isolation of regulatory
elements sequencing (FAIRE-Seq) evidence for altered chromatin accessibility in MCF7 cells at
enhancer site E due to hypoxic stimuli. Moreover, we did not identify HRE binding sites in
enhancer E, which is why we assume that region A1 is most likely to trigger the hypoxia-driven
upregulation of theMB exon 5u promoter.
Analyzing bisulfite-sequencing datasets of MCF7, LNCaP and MDA-MB468 cells revealed a
multitude of CpGs to be unmethylated in region A1, suggesting that specific CpG methylation
might be an additional mode of transcription regulation of theMB gene (S4 Table). Although no
information about the methylation status of the CpGs proximate to the HRE in region A1 was
given for LNCaP cells, they were detected as unmethylated in both breast cancer cell lines, thus
underlining the crucial role of this HRE in hypoxia-drivenMB expression (S4 Table and Fig 6a).
Fig 6. Evidence for potential functional sites in candidateMB regulatory regions. (a) Annotations of the hypoxia- and estrogen-responsive region A1.
Large boxes indicate ChIP-Seq peaks and an RNA PolII-ChIA-PET. Small boxes and arrowheads show in silico predicted transcription factor binding motifs.
CpGs whose methylation status has been revealed by bisulfite sequencing analyses are indicated (shown in detail in S4 Table). (b) Annotations of the
androgen-responsive region D1. The large boxes indicate AR-ChIP-Seq peaks, a DNAse I hypersensitive sites and a CTCF-ChIA-PET. Small boxes show
the locations of predicted transcription factor binding motifs (AREs).
doi:10.1371/journal.pone.0142662.g006
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Hormone-driven chromatin modifications atMB enhancer sites
According to RNA-Seq data, treatment of LNCaP cells with androgens associated with a
decrease ofMBmRNA levels (Fig 2a). Thus, androgen treatment may impact onMB gene reg-
ulatory elements to cause a repression of transcriptional activity. DLRAs performed on LNCaP
cells transfected with theMB exon 5u promoter constructs revealed that the promoter itself
does not alter transcription efficiency upon DHT treatment (Figure b in S3 Fig). Therefore
most likely, the effect ofMB downregulation mediated by DHT occurs by interaction of the
promoter with hormone-responsive enhancer sites. DLRAs revealed that none of the potential
MB-regulating DNA regions studied as isolated DNA fragments enhanced activity in LNCaP
cells if DHT-treated (Figure b in S3 Fig), but regions A1, B, C, D1, D2 and G slightly decreased
reporter gene activity by 17 to 34% (Figure b in S3 Fig). Irrespective of androgen treatment,
most regions that potentially loop back to theMB exon 5u promoter in LNCaP cells in vivo fea-
tured an open chromatin status (Figure a in S3 Fig). Part of region D1, however, only featured
DNAse I peaks in the presence of androgens, highlighting this region as a candidate for hor-
mone-responsiveness. Analysis of AR-ChIP-Seq data from LNCaP cells further revealed ChIP
peaks in region D1 only present upon DHT treatment (Figure a in S3 Fig). Within this ChIP
peak, region D1 contains three candidate androgen-responsive elements (ARE), identified by
bioinformatic motif predictions (Fig 6b). This accumulation of evidence renders D1 a most
promising candidate for androgen-mediated regulation in prostate cancer cells.
In a parallel analysis, we investigated hormone regulation ofMB in MCF7 breast cancer
cells, where estrogen triggered a decrease inMBmRNA levels (Fig 2b). Except for region A2,
all candidate sites that interact with theMB promoter and the promoter itself revealed an open
chromatin status both upon and without E2 treatment (Figure a in S4 Fig). Analysis of ChIP--
Seq datasets using estrogen receptor α (ERα) antibodies on E2-treated MCF7 cells pointed out
those DNA regions where transcription factors bind specifically upon addition of E2. In pres-
ence of the hormone, region A1 showed binding of the transcription factor complexes p300,
RNA-Pol II and ERα (Figure a in S4 Fig). Thus, A1 is likely to play a crucial role in the
E2-mediated regulation ofMB transcription. In addition, we found ERα associated complexes
to interact with DNA regions C and G upon E2 treatment, though the ChIP-peaks were only
detected in one dataset each (Figure a in S4 Fig). Interaction of DNA region F with theMB
exon 5u promoter under E2 treatment was indicated by a dataset of MCF7 cells from the
ChIA-PET browser using ERα antibodies, although there were no additional ChIP-peaks
evidencing the binding of ERα to DNA region F (Fig 3 and Figure a in S4 Fig). DLRA measure-
ments in E2-treated MCF7 cells showed that neither theMB exon 5u promoter, nor any of the
candidate interacting regions acted as transcriptional enhancers. Therefore, none of these
DNA elements would counteract the experimentally determined E2-driven downregulation of
MB. DLRA measurements further revealed that DNA region A1 significantly decreased tran-
scriptional activity of the reporter gene construct by 27%, while theMB exon 5u promoter itself
and DNA regions C and G showed a slightly reduced transcriptional activity of 16% and 7%,
respectively (Figure b in S4 Fig). Four estrogen-responsive element (ERE) half sites and two
runt-related transcription factor 1 (RUNX1) binding sites were detected bioinformatically in
region A1 and possibly participate in the estrogen-driven downregulation ofMB transcription
in breast cancer cells.
Discussion
Myoglobin (MB), present at high concentrations in striated skeletal and heart myocytes, has
recently also been detected at lower expression levels in a variety of cancer specimen [23]. Con-
currently, the architecture of the humanMB gene has been revised by inclusion of several
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novel upstream exons, which produce alternatively spliced mRNAs originating at novel pro-
moter regions [21]. While the classicMB promoter (starting at exon 9u) only drives the tran-
scription ofMB in muscle cells,MB transcription in epithelial cancer cell lines and tumor
entities is predominantly regulated by a novel, more upstream promoter starting at exon 5u
[21]. Since MB expression apparently correlates with a more benign breast and prostate tumor
phenotype [15, 18] it will be important to understand its gene regulation in the context of
cancer.
Breast and prostate cancer cells predominantly express alternativeMB
transcripts
Our in silico and qRT-PCR studies showed a predominant expression of alternative, non-stan-
dardMBmRNAs in MCF7 breast cancer and LNCaP prostate cancer cells. TheMB transcript
variants driven by the exon 5u upstream promoter were most abundantly expressed in these
cell lines. At a minor level, transcripts starting at exon 4u were also detected, whileMB tran-
scripts initiated at the myocyte-active gene promoter were only found in minute amounts.
These results were in full agreement with previously published quantitative data onMB splice
variant amounts in MDA-MB468 breast cancer, DLD-1 colon cancer cells [21] and hematopoi-
etic stem/progenitor cells [24]. By mining of epigenetic data (e.g. by ENCODE), we obtained
broad evidence for the dominant activity and accessibility of theMB exon 5u promoter in can-
cer cells, while the classic myocyte-typeMB promoter approved silent (Fig 4b). The data
revealed a complex network of candidate enhancer sites that potentially interact with theMB
exon 5u promoter to regulate its activity in cancer cells with respect to hypoxia and hormone
stimuli.
MB upregulation under hypoxia
In myocytes,MB expression is not inducible by hypoxia alone, but requires additional stimuli
such as exercise [25]. Accordingly, the classicMB promoter lacks candidate HRE motifs [26].
In contrast, hypoxia induction of MB protein and mRNA was previously reported in HBEC/
3KT, MCF7, MDA-MB468, DLD-1, HTB182 and renal cell carcinoma cell lines
[14,16,17,20,21]. We show here that expression ofMB exon 5u transcripts increased 2.8 fold
and 4.3 fold in LNCaP and MCF7 cells, respectively, after 24 h at 1% O2 (Fig 1b and 1c). Up to
now, we have a rather vague understanding of the impact of hypoxia and the precise contribu-
tion of HIF-dependent and -independent cascades on the regulation of theMB gene (e.g. [20]).
One candidate HRE, upregulatingMB by 43% under hypoxia in vitro, was recently described
downstream ofMB exon 7u [20]. Our current bioinformatic analyses in MCF7 cells, however,
did not corroborate a prominent role of the exon 7u-linked HRE in the hypoxia regulation of
MB. We thus focused on the detection of other, novel enhancer sites that may facilitate—even
via long-distance activation—the hypoxia inducibility of theMB gene.
In LNCaP and MCF7 cells, theMB exon 5u promoter itself did not account for hypoxia sen-
sitivity, as shown by reporter gene assays (Fig 5b and 5c). Instead, our studies revealed a candi-
date enhancer site A1 in ~250kb distance to the promoter, which is hypoxia-responsive as
confirmed by DLRA assays. Region A1 interacts with the promoter, as evidenced by PolII
ChIA-PETs fromMCF7 cells and features an open chromatin status according to FAIRE-Seq
and DNAse I HS data (Figs 3 and 5a). The HIF1α ChIP-Seq peak in hypoxic MCF7 cells,
which harbors a potential HRE sequence motif, lends additional evidence to a hypoxia respon-
sive role of region A1. Bisulfite sequencing data further revealed the methylation status of four
CpGs around the HRE (Fig 6a), which are all unmethylated in MCF7 and MDA-MB468, thus
allowing for hypoxia-inducibility of theMB gene. In addition, several other DNA elements
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around theMB gene may form additional interactions with the A1 enhancer for full stimula-
tion of the promoter (Fig 7a), as suggested by the open chromatin status of regions B, C, D2, F
and G under normoxia and hypoxia according to FAIRE-Seq and DNAse I HS tracks (Fig 5a).
The discovery of the HIF-bound HRE enhancer site provides a mechanistic basis for the find-
ing that siRNA knockdown of HIF1α and HIF2αmost efficiently counteracts induction ofMB
mRNA after 72 h under 1% O2 [20]. Importantly,MB upregulation by hypoxia does not only
occur in various cell lines, but also in a broad range of epithelial cancer tumor entities
[17,18,20,21]. However, the molecular function of hypoxia-upregulated, but still low-level
expressed MB in tumor cells is currently unclear. As in smooth muscle cells [11], it is possible
that deoxy-MB functions in hypoxic regions of epithelial cancers by producing NO, thereby
activating NO signalling. Alternatively, MB may scavenge harmful ROS produced by intense
fatty acid metabolism [27]. We further found a decreased mitochondrial dehydrogenase activ-
ity in MB-proficient MDA-MB468 breast cancer cells under stringent hypoxia (0.2% O2), com-
pared to siRNA-mediatedMB knockdown cells, suggesting that deoxy-MB is indeed able to
exert unexpected respiration-delimiting functions in O2-deprived cancer cells [20]. Although
the tumor suppressing effect of hypoxia-regulated MB expression in cancer cells thus possibly
relies on the globin’s ability to either produce or scavenge NO/ROS, additional experiments are
needed to specify MB’s suppressive role in tumors.
Estrogen-mediated downregulation ofMB expression in breast cancer
cells
In addition to hypoxia regulation ofMB, we previously discovered that exposure of ERα-posi-
tive [28] MCF7 breast cancer cells to 17β-estradiol (E2) resulted in a dose-dependent downre-
gulation ofMB [15]. Our results approved that expression of exon 5uMB transcripts, and also
to a lesser extent of exon 4u mRNAs, significantly decreased upon hormone treatment in a
time-dependent manner. Several lines of evidence support the hypothesis that the promoter
itself is not hormone-responsive, but candidate enhancer sites are involved: (i) most candidate
regions revealed open chromatin in both, E2-treated and -untreated MCF7 cells, (ii) ChIP-Seq
data revealed binding of ERα after E2 treatment in DNA regions A1 (in four independent data-
sets), C and G, (iii) additional ChIP-Seq data supported p300 activator and RNA PolII binding
in E2-treated cell batches only, and (iv) region A1 suppressed reportergene transcription in
MCF7 cells after estrogen treatment (Fig 4c, S4 Fig). Transcription factor binding motif
searches revealed a combination of SP1 boxes, RUNX1 motifs and ERE half sites in region A1,
which are hypothetically involved in the hormone regulation of theMB exon 5u promoter.
Based on ChIA-PET data mining, DNA regions A1 and C potentially associate in a cloverleaf-
like loop architecture together with regions B and D1 to interact with theMB promoter under
E2 treatment (Fig 7b). Three general mechanisms have been described for ERα/E2-mediated
downregulation of target genes [29–31]. Of those, the “squelching model”, implying a displace-
ment of transcription factor p300 from the repressed target gene [29], appears unlikely in the
MB case, since we observed a p300 ChIP-Seq peak in region A1 after E2 treatment. Instead,
transcriptional silencing ofMBmight have occurred via active recruitment of repressor-com-
plex factors such as FOXA1 and HDAC7 [30] or by the repressor of estrogen receptor activity
(REA) in combination with HDAC1 and HDAC2 [31].
In our working model, region A1 may represent a bi-functional gene regulatory element for
MB, acting as an enhancer ofMB transcription under hypoxia, and participating in downregu-
lation upon estrogen exposure in an ER-positive background. Exon 5uMBmRNA expression
in MCF7 cells was decreased by 30% already after 10 min and by 60% after 24 h upon E2 treat-
ment (Fig 2b and S1b Fig).MB hypoxia regulation, in contrast, peaked after 72 h [20]. Thus,
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Fig 7. MB exon 5u promoter regulatory networks in tumor cells under different conditions. (a)Hypoxia
(1%O2)-driven upregulation of the promoter in MCF7 cells. HIF1α/β binding to the candidate HRE in region
A1 is indicated (Fig 6a). Regions G and F interact with RNA-PolII. Open chromatin regions are drawn in black
(Fig 5a). (b) Estrogen (E2)-mediated downregulation of the promoter in MCF7 cells. ERα binding to region A1
may occur at the ERα-half sites and the RUNX1 site (see Fig 6a for details). The complex bound to region A1
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the hormone response appeared to occur much faster than the hypoxia response. We conclude
that thoughMB expression might be downregulated by E2 treatment via enhancer A1 after a
few minutes up to few hours, the strongest HIF1 response ofMB was reported one to three
days post hypoxia stimulus and thus must not necessarily interfere with the early E2 response.
In well-differentiated invasive ductal breast carcinomas, MB was described to be co-
expressed with ERα and thus adds prognostic information to ERα-positive patient tumors
[15,20]. Tumors of pre-menopausal patients revealed lower MB expression levels than those of
post-menopausal patients [15]. We therefore expect the E2-mediated suppression ofMB tran-
scription in ERα positive breast tumors to be weakened, once E2 levels start to decrease in
post-menopausal females. It is also not clear how the inherently more aggressive ER-negative
and triple-negative (ER-, PR-, Her2-) breast cancer cells such as MDA-MB468 [28,32,33] will
respond inMB expression when subjected to E2.
Androgen downregulatesMB in prostate cancer cells
Analogous to the E2 response in breast cancer, androgens were found to downregulateMB
mRNA expression in prostate cancer cells. Our in silico analyses indicated that treatment of
LNCaP cells with the potent, non-aromatizable R1881 androgen tended to decreaseMB exon
5u transcripts to 64%, 32% and 16% of control levels after 12, 24 and 48 h of hormone expo-
sure, respectively (Fig 2a and S2 Fig). This result is in line with a significant decrease of overall
MB transcription described in LNCaP cells subjected to DHT for 16 h [18].
To unveil the regulatory network orchestrating the decrease ofMB expression upon andro-
gen treatment, we studied the enhancer activity of DNA regions which interact with theMB
exon 5u promoter according to ChIA-PET data. Similar to the estradiol-mediated gene regula-
tion, reporter gene assays revealed that theMB exon 5u promoter did not alter transcriptional
activity in DHT-treated LNCaP cells. In contrast, a subset of candidate enhancer regions,
which interact with theMB exon 5u promoter, slightly decreased transcription in vitro. Mining
of three prostate cancer cell ChIP-Seq datasets revealed region D1, encoding an ARE sequence
motif, to be bound by AR specifically upon DHT treatment. Moreover, DNAse I datasets
proved accessibility of D1 for transcription factors in androgen-supplemented LNCaP cells.
The looping chromatin structure of regions A1, B, C and D1 that we hypothesize to be formed
in breast cancer cells to drive the E2-stimulated transcription repression ofMB could also be
formed in LNCaP cells in response to DHT treatment (Fig 7c). Like in the ERα scenario, the
chromatin interaction network in LNCaP cells is likely to recruit AR repressor complex pro-
teins to the promoter (Fig 7b) to mediate transcriptional repression ofMB under androgen
treatment [34,35].
In prostate cancer biopsies, immunohistochemistry staining revealed a co-localization of
MB with AR and FOXA1 [18]. According to in silico data, LNCaP cells express elevated levels
ofMB after 3 weeks of androgen deprivation, compared with hormone-naive control cells
treated with androgens [18]. A therapeutical approach to combat hormone-naive prostate can-
cer is to treat patients with androgen antagonists, thus preventing the AR from activating genes
associated with tumor growth and survival. Based on our results, we assume that this therapy
further interacts with p300 and RNA-PolII. Regions C and G also interact with the ERα protein complex,
region F associates with RNA-PolII (Figure a in S4 Fig). This interaction network recruits a repressor complex
to downregulate the transcription of 5uMB transcripts under E2 treatment. Open chromatin regions are
marked in black. (c) Androgen (DHT)-driven downregulation of the promoter in LNCaP cells. AR binding to a
hypothetical AREmotif in region D1 (Fig 6b) is indicated. Region A2 interacts with RNA-PolII. This interaction
network recruits a repressor complex to downregulate the transcription of exon 5uMB transcripts under DHT
treatment. Open chromatin regions are marked in black (Figure a in S3 Fig).
doi:10.1371/journal.pone.0142662.g007
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would prevent an AR-mediated decrease ofMB transcripts, thereby indirectly ensuring higher
levels ofMB expression in prostate tumor cells. IncreasedMB expression, being associated
with an ameliorated patient prognosis [18], could hypothetically contribute to the successful
outcome of anti-androgen tumor therapies.
In conclusion, the availability and detailed analysis of publically accessible high-throughput
epigenomic datasets present a formidable opportunity to dissect gene regulatory pathways of
biomedically important genes and to infer important working hypotheses for functional
studies.
Supporting Information
S1 Fig. Expression analysis ofMB transcript variants in MCF7 cells. (a) In silico quantifica-
tion ofMB transcripts by RNA-Seq analysis in normoxic and hypoxic (1% O2, 24 h) cancer
cells. Read counts are shown as RPKM values. Expression values are detailed in S1 Table. (b)
Start-site specificMB expression in MCF7 cells treated with 100 mM E2 for different time peri-
ods. GRO-Seq reads which mapped 100 bp upstream to 500 bp downstream to each start site
were counted and normalized to the fragments’ size and total reads of the dataset (in Mio).
Box plots of (n = 2–3) datasets for each time period represent the transcriptional levels ofMB
start exons ( p< 0.05). Average transcript-specific expression values are given in S1 Table.
(TIF)
S2 Fig. Expression ofMB transcript variants in LNCaP cells treated with 1 nM R1881 for
different time periods.MB start exon quantifications are shown as RPKM values for each
experiment, indicating the expression of according mRNA variants. Expression values are
detailed in S1 Table.
(TIF)
S3 Fig. Identification of androgen associated regulatory regions of theMB gene in LNCaP
cells. (a) UCSC browser overview of androgen associated chromatin modifications around the
5uMB promoter in LNCaP cells. Top: UCSC annotation ofMB and a custom track of all
humanMB exons, according to [21]. Bottom: UCSC browser and custom tracks. Dataset speci-
fications are listed on the right. The green shattered box indicates the 5uMB promoter region.
The red shattered boxes mark the DNA regions that directly interact with the 5uMB promoter
based on ChIA-PET data. The naming of the regions to match the DLRA measured constructs
is written in the bottom line. (b) Dihydrotestosterone inducibility of theMB 5u promoter and
interacting DNA regions in LNCaP cells. DLRAs were measured on 100 nM DHT treated (for
3 h) and control cells transfected with reportergene plasmids with different DNA regions.
Box plots indicate the average RLU fold change of each construct measured in hormone treated
versus control cells after normalization on empty vector constructs and renilla control vectors.
Standard deviations are indicated by error bars ( p< 0.05;  p< 0.01; n = 5).
(PDF)
S4 Fig. Identification of estrogen associated regulatory regions of theMB gene in MCF7
cells. (a) UCSC browser overview of estrogen associated chromatin modifications around the
5uMB promoter in MCF7 cells. Top: UCSC annotation of the humanMB gene and a custom
track of all humanMB exons, according to [21]. Bottom: UCSC browser and custom tracks.
Dataset specifications are listed on the right. The green shattered box indicates the 5uMB pro-
moter region. The red shattered boxes mark the DNA regions that directly interact with the 5u
MB promoter based on ChIA-PET data. The naming of the regions to match the DLRA mea-
sured constructs is written in the bottom line. (b) Estrogen inducibility of theMB 5u promoter
and interacting DNA regions in MCF7 cells. DLRAs were conducted on 100 nM E2 treated
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(for 1 h) and control cells transfected with reportergene plasmids with different DNA regions.
Box plots indicate the average RLU fold change of each construct measured in hormone treated
versus control cells after normalization on empty vector constructs and renilla control vectors.
Standard deviations are indicated by error bars ( p< 0.05;  p< 0.01;  p< 0.001; n = 3).
(PDF)
S1 Table. RNA-Seq and GRO-Seq datasets analyzed from the NCBI-Sequence Read
Archive. RNA-Seq reads mapping to eachMB start exon were counted and normalized as
RPKM values in order to estimate the average start-site specific expression of differentMB var-
iants. Detailed box plots of all studies are shown in Figs 1c, 2a and 2b and S1a, S1b, and S2 Figs.
(PDF)
S2 Table. Histone mark and bisulfite treated datasets processed, originating from different
databases.
(PDF)
S3 Table. List of all primers applied. Restriction enzyme recognition sites are underlined.
(PDF)
S4 Table. Methylation status of CpGs encoded in the 5uMB promoter and its potentially
interacting DNA regions A1 to G. Bisulfite Sequencing results of each datasets shown in the
headline are listed for chromosome 22 genome positions of potential enhancer regions. Due to
a lack of sequencing depth information was not provided for all CpG sites. The last column
indicates if the DNA site matches a UCSC browser annotated SNP.
(PDF)
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